Form 4 for IMRX Immuneering Corp
Accepted 2021-12-22 00:00:00 ET · period of report 2021-12-22 · accession 0001415889-21-006188 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-22 | 2021-12-22 | IMRX | Hall Brett Matthew | CSO | A - Grant | — | +322.7K | 329.1K | +5,048% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2021-12-22 | A | A | 322,691 | — | 329,084 | D | — | — | (F1) Calculated using a value based on the average of the daily volume weighted average prices of the Class A common stock on the Nasdaq Stock Exchange for the 30-trading day period ending on and including the trading day immediately prior to the Closing Date, as that term is defined in the Share Purchase Agreement, dated as of December 22, 2021, by and among Immuneering Corporation, BioArkive, Inc. ("BioArkive"), and each of the shareholders of BioArkive, including Dr. Hall. |